All In Biotech

Drug Trial Radar · NCT01474083

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GK1-399 in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Sep 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Nov 2011

Primary completion

Aug 2012

Study completion Sep 2012

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4 treatments will be placebo, which does not contain an active ingredient. The study participation includes in-patient and out-patient days.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • GK1-399 (formerly TTP399)Drug

    Treatment A: GK1-399 200 mg. Oral administration, twice per day.

  • GK1-399 (formerly TTP399)Drug

    Treatment B: GK1-399 800 mg. Oral administration, once per day.

  • GK1-399 (formerly TTP399)Drug

    Treatment C: GK1-399 800 mg. Oral administration, twice per day.

  • PlaceboDrug

    Dose-matched placebo. Oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameters of GK1-399 from plasma concentrationsTime frame: 52 time points over a 6 week period

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Forest Investigative Site 009

    Little Rock, Arkansas

  • Forest Investigative Site 006

    Chula Vista, California

  • Forest Investigative Site 002

    DeLand, Florida

  • Forest Investigative Site 001

    Miami, Florida

  • Forest Investigative Site 010

    Overland Park, Kansas

  • Forest Investigative site 011

    Saint Paul, Minnesota

  • Forest Investigative Site 005

    Springfield, Missouri

  • Forest Investigative Site 003

    Neptune City, New Jersey

  • Forest Investigative Site 008

    Willingboro, New Jersey

  • Forest Investigative Site 007

    New York, New York

  • Forest Investigative Site 004

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.